While the regulations themselves remain unchanged, the new version 4.0 guidance, implemented in March 2026, offers important direction on compliance expectations, signaling an evolution in Health Canada’s approach to GMP oversight.
Increasingly, the focus is not simply on identifying GMP deficiencies during an inspection, but on how companies assess their significance, identify and implement corrective and preventive actions (CAPAs), and ensure that those actions are effective. It reflects Health Canada’s expectation that companies move beyond correcting individual observations and strengthen quality systems to identify systemic issues, address root causes and prevent recurrence.
This evolution becomes clearer when viewed in the context of Health Canada’s inspection experience. The 2021–2022 NHP GMP Inspection Pilot Program marked the beginning of a more proactive approach to GMP oversight and set the stage for routine onsite inspections. These inspections provided Health Canada with a meaningful opportunity to verify GMP compliance beyond the paper-based site licensing process.
While many firms demonstrated effective quality systems, the inspections also identified significant deficiencies, with many companies being advised of potential or immediate site or product licence suspensions. These experiences gave Health Canada a much clearer understanding of where compliance gaps existed and help explain many of the themes reflected in the revised guide.
Perhaps the clearest example is the guide’s expanded discussion of risk classification of GMP observations and the CAPA process. Although CAPA has always been an essential component of an effective quality system, the revised guide provides much greater clarity on Health Canada’s expectations for evaluating non-conformances, assessing risk, conducting root cause investigations, implementing corrective and preventive actions, and verifying their effectiveness.
Significantly, guidance on the CAPA process, previously communicated in a standalone Health Canada bulletin, has now been directly incorporated into the guide. This emphasis aligns with our experience supporting companies through Health Canada inspections, where the quality of a company’s CAPA process is often viewed as a strong indication of the maturity and effectiveness of its quality system.
From a practical perspective, identifying a GMP observation during an inspection is only the beginning. Inspectors expect companies to demonstrate how they assessed the significance of the observation, determined whether it represented an isolated event or a systemic issue, identified the underlying root cause, implemented corrective and preventive actions proportionate to the level of risk, and verified that those actions effectively addressed the problem.
The revised guide also reinforces Health Canada’s expectations for oversight throughout the supply chain. Importers, in particular, should recognize that responsibility for product quality cannot simply be delegated to foreign parties through contractual agreements. Demonstrating appropriate supplier oversight and ensuring that GMP requirements are consistently met throughout the supply chain remain essential responsibilities.
Ultimately, Version 4.0 of the GMP Guide reflects the maturation of Health Canada’s NHP compliance program and signals a move toward risk-based oversight, effective quality management and evidence-based decision making. For industry, the message is clear: The inspection no longer ends with the observation, Health Canada is interested in what happens next.
The revised guide represents a shift from observations to outcomes. Companies that recognize this shift and build quality systems capable of demonstrating continual improvement will be better positioned not only for future inspections, but ultimately to strengthen product quality and consumer confidence.
